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ABSTRACT
The study was undertaken to determine transmission of Mycobacterium tuberculosis within the prison envi-
ronment. In total, 168 Aba Federal prison inmates in Nigeria were evaluated for tuberculosis (TB) by spu- 
tum-smear microscopy and sputum culture, simultaneously, and for HIV status by serology. They were sub-
sequently followed up for one year for fresh Mycobacterium-associated infection by tuberculin skin testing 
or for development of TB and for HIV infection or AIDS. Ninety-one (54.2%) of the 168 prison inmates had 
infection due to Mycobacterium, and three (3.3%) of them were sputum-smear- and culture-positive while 
41 (24.4%), including one (2.4%) with concomitant TB, were HIV-infected. In a one-year follow-up study, 
11 (19.3%) of 57 tuberculin skin test (TST)- and HIV-negative inmates became TST-positive and one (1.8%) 
HIV-positive, eight (13.8%) of the 58 TST-positive but HIV-negative inmates developed TB, and one (1.7%) 
became HIV-infected: six (24.0%) of 25 TST- and HIV-positive inmates developed TB while five (33.3%) of 
15 TST-negative but HIV-positive inmates became TST-positive, and one (6.7%) progressed to AIDS. The 
duration of imprisonment did not influence the rates of infection, and the transmission of Mycobacterium 
tuberculosis did not necessarily require sharing a cell with a TB case. 
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INTRODUCTION
Tuberculosis (TB), one of the most important con-
tagious diseases, is a leading cause of death due to 
a single pathogen worldwide. Patients with pul-
monary TB would broadcast the tubercle bacilli in 
droplet aerosols as they cough, sneeze, or even talk 
and infect those in contact. A person with untreat-
ed pulmonary TB is estimated, on average, to infect 
10-15 persons annually (1). A primary infection due 
to Mycobacterium tuberculosis may actively develop 
into clinical TB, pass as inapparent infection, or re-
main latent in the individual for months or years 
depending on the various host and environmen-
tal factors. Overt TB, thus, could result from a re-
activated latent infection or from a recent primary 
infection or (secondary) re-infection. It has been 
observed that the transmission of M. tuberculosis is 
favoured by dusty environment and overcrowding. 
Infections can be acquired by both close and casual 
contacts. The risk of becoming infected depends on 
such factors as the relative virulence of the strain, 
the intensity of exposure to an infectious TB case 
(closeness and duration), and the susceptibility and 
immune status of the exposed individual (2,3). 
Mitsos et al. observed that only a small proportion 
of individuals infected with M. tuberculosis devel-
op clinical TB (4), and even then, a wide clinical 
spectrum of severity of disease is observed in such 
individuals. A lifestyle, such as tobacco/cigarette 
smoking, could increase the chances of developing 
clinical TB four-fold (5-7) due to the various effects 
of smoking on components of both innate and 
adaptive immunity (8-11). Exposure to indoor air 
pollution has been associated with TB among other 
broncho-pulmonary diseases (12). Epidemiologic 
studies have shown that risk of TB increases with 
close contacts of sputum-smear-positive patients 
and that the prevalence of clinical disease among 
intimate contacts of TB cases is high (13-15).
HIV infection has become an additional factor 
that has specifically threatened TB programmes 
worldwide, and for the last two decades, the HIV Chigbu LN and Iroegbu CU Transmission of Mycobacterium tuberculosis in Nigerian prison
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pandemic and TB have been inextricably linked. 
TB has become the most common cause of death 
among HIV-infected adults in less-developed coun-
tries (16). In sub-Saharan Africa where ≈70% of 
HIV-infected individuals of the world live, the an-
nual rate of identification of TB cases has quadru-
pled since the mid-1980s (17), and over two-thirds 
of TB patients in the region are dually infected with 
HIV (18). It is estimated that about 200,000 deaths 
due to TB occur among the people of sub-Saharan 
Africa concomitantly infected with HIV (19).
The factors influencing infection and progression 
to TB and even AIDS tend to prevail in crowded 
institutions, such as military camps, prisons, and 
police detention camps. The Nigerian prisons seem 
most favourable for the dissemination of M. tubercu- 
losis and progression to TB and transmission of HIV 
and progression to AIDS given the overcrowding in 
cells, poor feeding, and allegations of homosexual 
practices and sexual abuse among the incarcerated.   
It was on account of these that the investigation 
reported here was carried out among the inmates 
of the Federal prisons in Aba, Nigeria. 
MATERIALS AND METHODS
Sample 
The sample consisted of 168 male prisoners, aged 
20-63 years (mean age 33.8 years), who had been 
incarcerated from two days to 13 years. They were 
accommodated in four cells designated C, D, H, 
and I respectively, each measuring about  12.2 m x 
12.2 m x 3.7 m. There were 65 inmates in Cell C, 35 
in Cell D, 26 in Cell H, and 42 in Cell I. The prison-
ers were allowed two hours each to come out and 
stretch their limbs, bask themselves in sunshine,   
and breathe fresh air or more hours if they were 
assigned to outdoor labour. Feeding was generally 
poor, and food from relatives and Church organiza-
tions or charities visiting the prisons was permitted 
following a strict screening for safety. Individual 
characteristics of the prisoners, such as lifestyle, 
history of smoking, alcohol consumption, sexual 
behaviours, and history of TB or contact with TB 
patient, were sought and voluntarily given by 
the inmates. A Prisons Medical Unit with trained 
paramedical personnel in charge treated minor ail-
ments and referred cases with persistent respiratory 
symptoms to the hospital. The investigation start-
ed with inmates brought to the Chest Clinic of the 
ABSUTH for clinical evaluation and treatment from 
June to November 2006. They were followed to the 
prison, and other inmates were investigated either 
for similar symptoms or as contacts. 
Collection and examination of sputum
Early-morning sputum specimens were obtained 
from the patients in three consecutive days in ster-
ile wide-mouthed disposable containers (Sterilin). 
The sputum was processed using a modification of 
the Baltimore Biological Laboratories (BBL) meth-
od (20). To the sputum in a test-tube was added 
an equal volume of 4% (w/v) NaOH containing 
phenol red indicator, vortexed to homogenize, and 
stored at room temperature (≈27 oC) for 30 minutes 
to digest. The mixture was subsequently neutralized 
with an equal volume of 2N HCl and centrifuged at 
3,000 rpm for five minutes in a Gallenkamp bench-
top centrifuge. The supernatant was discarded, and 
a portion of the sediment was used for making 
three smears on three clean grease-free slides, air-
dried, and heat-fixed. The smears were then stained 
with concentrated carbol-fuschin (primary stain), 
steamed for five minutes in the first instance, and 
further for three minutes after adding fresh stain. 
Thereafter, the slides were rinsed with water, de-
colourized with 3% HCL/ethanol mixture until 
the stain was no more visible, and then counter-
stained with methylene blue for two minutes be-
fore rinsing with water and drying for microscopic 
examination.
Isolation and characterization of Mycobacte-
rium tuberculosis from sputum specimens
Both NaOH-digested and undigested sputum speci-
mens were inoculated onto separate screw-capped 
bottles of the modified Lowenstein-Jensen (L-J) egg 
medium prepared as follows: first, a mineral salt so-
lution, containing KH2PO4 (0.4%w/v), MgSO4.7H2O 
(0.4%w/v), magnesium citrate (0.1%w/v), asparagines 
(0.6%w/v), and glycerol (2%v/v), was prepared with 
distilled water and sterilized by autoclaving at  121 
oC for 15 minutes. To 300 mL of this solution was 
added 10-20 mL of sterile 2% Malachite green so-
lution and the contents of 12-16 freshly-laid hen’s 
eggs (aseptically). The mixture was homogenized in 
a previously-sterilized Warren blender, and the ho-
mogenate was dispensed in 6-7 mL volumes into 
sterile screw-capped disposable universal bottles 
(Sterilin). The L-J medium so dispensed was further 
sterilized by inspissations for 45 minutes in slanted 
position in a water bath at 85 oC.
Each inoculated L-J medium was incubated at 37 oC 
for 8-10 weeks, observing it daily for growth. Cul-
tures showing no significant growth after 10 weeks 
were discarded. Smears made from the emergent 
colonies on the L-J slopes were stained by the Ziehl-
Neelsen method and examined microscopically for 
acid-fast bacilli (AFB). AFB-positive colonies were 
further tested for nitrate reduction, niacin and cata-
lase production respectively and for hydrolysis of 
Tween-80 at the TB Unit of the Nigerian Institute 
for  Medical  Research,  Yaba,  Lagos,  using  standard 
bacteriological techniques. Chigbu LN and Iroegbu CU
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Screening for exposure to Mycobacteriun 
species by tuberculin skin test
The tuberculin skin test (TST) was done using the 
Mantoux method. Approximately 0.1 mL of 5 tu-
berculin units per litre (5 TU/L) of PPD (Evans Me-
dia, USA) was inoculated intradermally on top of 
the fore arm ≈6 cm below the elbow. The site of 
inoculation was examined for the development 
of indurations 72 hours after as recommended by 
the American Thoracic Society and the Centers for 
Disease Control and Prevention (21). For individu-
als who tested HIV-negative, skin indurations of 
≥10 mm in diameter were recorded as TST-positive 
(TST+) while those with indurations of <10 mm in 
diameter were recorded as negative. For the HIV-
positive individuals, indurations of ≥5 mm in di-
ameter were taken as TST+ but those of <5 mm were 
recorded TST-.
Screening of patients for HIV antibodies
Approximately 4.0 mL of venous blood was collect-
ed and allowed to clot in a sterile disposable tube. 
The resulting serum was aspirated, centrifuged to 
clarify, and assayed for presence of HIV antibodies 
using Immunocomb II (Organics Ltd., Yavne 70650, 
Israel) and ELISA (SUDS HIV 1 and 2; Murex Diag-
nostic) test-kits. 
Follow-up study for TST/TB and HIV/AIDS
A one-year (December 2006–January 2007) follow-
up study was carried out with the prison inmates. 
Those diagnosed with concomitant TB and HIV 
infection were monitored for progression to AIDS, 
and those who were TST-positive but HIV-negative 
were followed to see the development of TB and/or 
HIV antibodies. Those who were HIV-positive but 
TST-negative were followed to see the progression 
to AIDS and/or TST-positive reaction or TB. Finally, 
those who were concomitantly positive for TST 
and HIV were monitored for progression to TB or 
AIDS or both. 
Ethical clearance
The study was carried out with permission of the 
Nigerian Prisons Service Corps, the Abia State Uni-
versity Teaching Hospital Research Board, and the 
University of Nigeria Biosafety Committee, after 
inspection of the facilities at the Infectious Diseases 
Hospital, Aba, Abia state, Nigeria, where the study 
was done.
RESULTS
Of the 168 prison inmates investigated, three (1.8%) 
were TB cases—one each in Cell C, H, and I, and 
none in Cell D. The TB case in Cell H had concomi-
tant TB and HIV infection. Of the 65 inmates in 
Cell C sharing the accommodation with the sin-
gle TB case, 38 (58.5%) reacted positive to TST, 
and seven (10.8%) of these were also HIV-positive. 
Cell H contained 24 inmates in addition to the TB 
case, and of them, 10 (41.7%) were TST-positive, 
and three (11.5%) of these TST-positive individuals 
were HIV-infected. In Cell D housing 35 inmates, 
among whom was no TB case, 20 (57.1%) tested 
TST-positive, with 13 (37.1%) of them being con-
comitantly infected with HIV and seven (20.0%) 
singly HIV-positive. In Cell I with one TB case and 
41 other inmates (contacts), 20 (47.6%) of the latter 
reacted TST-positive, and two (4.8%) of them were 
concomitantly infected with HIV (Table 1).
Table 2 shows the age distribution of the TB cases, 
concomitantly TB- and HIV-positive, TST-pos-
itive, concomitantly TST- and HIV-positive, singly 
TST- and HIV-positive individuals. Of the three di-
agnosed TB cases, one (2.7%) was among the 37 
inmates in the age-group of 18-26 years, and two 
(3.8%), including one concomitantly infected by 
HIV, came from the group of 80 inmates aged 27-
35 years. The highest frequency (66.7%) of the TST-
positive individuals, including four (19.0%) who 
tested HIV-positive, came from the group aged over 
44 years.  
Table 3 shows the distribution of the TB/TST and 
HIV-positive inmates according to the duration 





No. (%) of inmates positive Total
TB+ TB+ with 
HIV+ TST+ TST+HIV+ HIV+ TB+/TST+* HIV+$ 
C 65 1 (1.5) 0 (0.0) 31 (47.7) 7 (10.8) 6 (9.2) 39 (60.0) 13 (20.0)
D 35 0 (0.0) 0 (0.0) 7 (20.0) 13 (37.1) 7 (20.0) 20 (57.1) 20 (57.1)
H 26 0 (0.0) 1 (3.8) 7 (26.9) 3 (11.5) 2 (7.7) 11 (42.3) 6 (23.1)
I 42 1 (2.4) 0 (0.0) 18 (42.9) 2 (4.8) 0 (0.0) 21 (50.0) 2 (4.8)
Total 168 2 (1.2) 1 (0.6) 63 (37.5) 25 (14.9) 15 (8.9) 91 (54.2) 41 (24.4)
*All TB- and TST-positive cases with or without HIV infection; $All HIV-positive cases with or without 
TB or M. tuberculosis-associated infection; HIV=Human immunodeficiency virus; TB=Tuberculosis; 
TST=Tuberculin skin testChigbu LN and Iroegbu CU Transmission of Mycobacterium tuberculosis in Nigerian prison
JHPN 330





No. (%) of inmates positive Total
TB+ TB+HIV+ TST+ TST+HIV+ HIV+ TB+/TST+* HIV+$
18-26 37 1 (2.7) 0 (0.0) 17 (45.9) 3 (8.1) 3 (8.1) 21 (56.8) 6 (16.2)
27-35 80 1 (1.3) 1 (1.3) 24 (30.0) 14 (17.5) 5 (6.3) 40 (50.0) 19 (23.8)
36-44 30 0 (0.0) 0 (0.0) 12 (40.0) 4 (13.3) 5 (16.7) 16 (53.3) 9 (30.0)
>44 21 0 (0.0) 0 (0.0) 10 (47.6) 4 (19.0) 2 (9.5) 14 (66.7) 6 (28.6)
Total 168 2 (1.2) 1 (0.6) 63 (37.5) 25 (14.9) 15 (8.9) 91 (54.2) 40 (23.8)
*All TB- and TST-positive cases with or without HIV infection; $All HIV-positive cases with or without 
TB or M. tuberculosis-associated infection; HIV=Human immunodeficiency virus; TB=Tuberculosis; 
TST=Tuberculin skin test 
Table 3. Distribution of TB/tuberculin skin test-positive and HIV-infected prison inmates  by duration 






No. (%) of inmates positive Total
TB+ TB+HIV+ TST+ TST+HIV+ HIV+ TB+/TST+* HIV+$
≤6 23 0 (0.0) 0 (0.0) 8 (34.8) 1 (4.3) 4 (17.4) 9 (39.1) 5 (21.7)
7-12 29 1 (3.4) 1 (3.4) 6 (20.7) 3 (10.3) 1 (3.4) 11 (37.9) 5 (17.2)
13-18 12 0 (0.0) 0 (0.0) 7 (50.3) 1 (8.3) 0 (0.0) 8 (66.7) 1 (8.3)
19-24 20 0 (0.0) 0 (0.0) 11(55.0) 1 (5.0) 1 (5.0) 12 (60.0) 2 (10.0)
25-30 5 0 (0.0) 0 (0.0) 1 (20.0) 1 (20.0) 1 (20.0) 2 (40.0) 2 (40.0)
31-36 37 1 (2.7) 0 (0.0) 8 (21.6) 11 (29.7) 3 (8.1) 20 (54.1) 14 (37.8)
37-42 7 0 (0.0) 0 (0.0) 0 (0.0) 3 (42.9) 1 (14.3) 3 (42.9) 4 (57.1)
42-48 12 0 (0.0) 0 (0.0) 6 (50.0) 3 (25.0) 0 (0.0) 9 (75.0) 3 (25.0)
>48 23 0 (0.0) 0 (0.0) 11(47.8) 1 (4.3) 0 (0.0) 12 (52.2) 1 (4.3)
Total 168 2 (1.2) 1 (0.6) 58(34.5) 25 (14.9) 11 (6.5) 86 (51.2) 37 (22.0)
*All TB- and TST-positive cases with or without HIV infection; $All HIV-positive cases with or without 
TB or M. tuberculosis-associated infection; HIV=Human immunodeficiency virus; TB=Tuberculosis; 
TST=Tuberculin skin test 
of stay (months) in the prison at the time of the 
study. The lowest proportion (39.1%) of the in-
mates who tested TST-positive was among those 
who had stayed for ≤6 months, and the highest 
(75.0%) was among 12 inmates who had stayed for 
42-48 months. The 23 inmates who had stayed for 
≤6 months (but not shown in Table 3) included 11 
(47.8%) inmates who had spent between two days 
and three months in the prison. Of the latter, three 
(27.3%) tested TST+, including the inmate who 
spent only two days in the prison, three (27.3%) 
were singly HIV+, and one (9.1%) was concomi-
tantly TST+ with HIV+. Of the three diagnosed TB-
positive individuals, one in Cell C had spent seven 
months in the prison, one nine months in Cell 
H, and the third three years in Cell I. The range of 
duration of stay in the prison was two days to 13 
years, and the mean duration was 2.7 years. 
All the 168 inmates were also enlisted for follow-up 
but 155 (91.7%) were followed till January 2007, 12 
(7.1%) dropped on account of their discharge from 
the prison, and one (0.6%)—the TB-positive inmate 
in Cell I with concomitant HIV infection—died.   
Of the 155 inmates who completed the study, 83 
(53.5%) were those who were TST-positive, includ-
ing those who were concomitantly positive for TST 
and HIV, 15 were singly HIV-positive, and 57 were 
negative for both TST and HIV. Of the 83 TST-posi-
tive inmates, 14 (16.9%) developed TB confirmed 
by sputum-smear microscopy. These included six 
(24.0%) of the 25 inmates who initially reacted 
positive to both TST and HIV. Thus, eight (13.2%) 
were from a group of 58 inmates who tested TST-
positive but were HIV-negative at the beginning of 
the follow-up study. Of the 15 inmates who were 
singly HIV-positive at the beginning of follow-up, 
five (33.3%) became TST-positive, one (6.7%) de-
veloped AIDS, and none developed clinical TB. Of 
the 57 inmates who reacted negative to both TST 
and HIV, 11 (19.3%) became TST-positive and one 
(1.8%) HIV-positive (Table 4).
DISCUSSION
There were three diagnosed cases of TB among 
the 168 prison inmates investigated, and contacts 
of these inmates with 165 other prisoners would Chigbu LN and Iroegbu CU
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Table 4. Distribution of TB/tuberculin skin test-positive and HIV-infected individuals after a one-year 





No. (%) of inmates testing positive
TST+ TB+ HIV+ AIDS
TST- with HIV- 57 11 (19.3) 0 (0.0) 1 (1.8) 0 (0.0)
TST+ with HIV- 58 NA 8 (13.8) 1 (1.7) 0 (0.0)
TST+ with HIV+ 25 NA 6 (24.0) NA 0 (0.0)
TST- with HIV+ 15 5 (33.3) 0 (0.0) NA 1 (6.7)
Total 155 16 (10.3) 14 (9.0) 2 (1.3) 1 (0.6)
AIDS=Acquired immunodeficiency syndrome; HIV=Human immunodeficiency virus; NA=Not 
applicable; TB=Tuberculosis; TST=Tuberculin skin test
presumably put the latter at risk of infection with 
M. tuberculosis. It is not certain what proportion of 
the 52.4% other prisoners who tested TST-positive 
did so due to exposure to these three TB cases but 
10.3% of the TST-negative inmates in the one-year 
follow-up study, who became positive, strongly 
indicate transmission of M. tuberculosis-associated 
infection from TB cases to non-TB inmates within 
the prison. The TST-positive case rate (47.6%) in 
Cell D, which had no TB case, is within the range 
observed in cells with TB cases (Cell C–58.5%; Cell 
H–38.4%, and Cell I–47.7%). Thus, transmission did 
not require sleeping in the same room with a TB 
case. It would occur at other levels of contact and 
intimacy, including sharing work, eating, and rec-
reational environment. Some inmates were already 
exposed to infection due to M. tuberculosis outside 
before imprisonment given that four (36.4%) of 
the 11 inmates who had spent only ≤3 months in 
the prison at the time of screening, including the 
new inmate who had spent only two days, were 
TST-positive.
In addition to the transmission occurring in the 
prison as indicated by the earlier-mentioned 10.3% 
TST-negative inmates who became TST-positive 
within the one-year follow-up period, 33.3% of the 
TST- with HIV+ inmates who became TST-positive 
(i.e. TST+ with HIV+) compared to 19.3% from the 
TST- with HIV- individuals presumably reflect the 
impact of HIV on transmission of M. tuberculosis 
among contacts of the TB cases. HIV infection was 
also observed to influence progression of TST-posi-
tive state to overt TB in the 24.0% TST+ with HIV+ 
inmates who developed TB in the one-year follow-
up period compared to 13.2% of the TST+ with HIV- 
individuals. In 1993, it was estimated that about 
9% of global TB cases were attributable to HIV in-
fection, and it was forecast that this would rise to 
14% by 2000 (22).
Although the inmates were not screened for HIV 
at the inception of their incarceration, two of the 
115 HIV-negative individuals enlisted in the one-
year follow-up study became HIV-positive, and 
these are noteworthy because one had spent one 
year and another had spent two years at the time of 
initial screening when they tested negative. Thus, 
the transmission of HIV was also apparent among 
the inmates, which may be either through secret 
drug-use or through homosexual intercourse. This 
further suggests that the high rate (24.3%) of HIV 
observed among the Aba Federal Prison inmates, 
may not all be infections acquired while outside 
the prison but some may have been acquired while 
in the prison. Although lifestyles, such as tobacco/
cigarette smoking and alcohol consumption, could 
increase the chances of developing clinical TB 
four-fold (5-7), with the limited data in this study, 
similar conclusions could not be drawn. Consider-
ing the duration of stay in the prison and the 
incidence rate of TB or M. tuberculosis and/or HIV 
infections, there seemed to be no significant differ-
ence between groups of different durations of im-
prisonment (χ2
cal=2.24, p<0.05), suggesting that M. 
tuberculosis and HIV infections individually may be 
single-hit events that may not be dependent on the 
duration of contacts by inmates.
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